Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced... Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients a a a a Sandra De Meyer , Erkki Lathouwers , Inge Dierynck , Els De Paepe , a a a Ben Van Baelen , Tony Vangeneugden , Sabrina Spinosa-Guzman , b c a Eric Lefebvre , Gaston Picchio and Marie-Pierre de Be ´ thune Objective: Characterization of resistance development in virologic failure patients on the protease inhibitor darunavir administered with low-dose ritonavir (DRV/r) in the 48-week analysis of TMC114/r In Treatment-experienced pAtients Naive to lopinavir (TITAN). Design: TITAN is a randomized, controlled, open-label, phase III, noninferiority trial comparing the efficacy and safety of DRV/r with that of lopinavir/ritonavir (LPV/r) in HIV-1-infected, treatment-experienced, LPV-naive patients. The primary endpoint was the proportion of patients with HIV-1 RNA less than 400 copies/ml at week 48. Methods: Patients received DRV/r 600/100 mg twice daily (n¼ 298) or LPV/r 400/ 100 mg twice daily (n¼ 297), and an optimized background regimen. Patients who lost or never achieved HIV-1 RNA less than 400 copies/ml after week 16 were considered virologic failure patients. Genotyping and phenotyping were performed. Results: The virologic failure rate in the DRV/r arm (10%, n¼ 31) was lower than in the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png AIDS Wolters Kluwer Health

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients

AIDS , Volume 23 (14) – Sep 1, 2009

Loading next page...
 
/lp/wolters-kluwer-health/characterization-of-virologic-failure-patients-on-darunavir-ritonavir-xHkt0SFBJX

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0269-9370
eISSN
1473-5571
DOI
10.1097/QAD.0b013e32832cbcec
pmid
19474650
Publisher site
See Article on Publisher Site

Abstract

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients a a a a Sandra De Meyer , Erkki Lathouwers , Inge Dierynck , Els De Paepe , a a a Ben Van Baelen , Tony Vangeneugden , Sabrina Spinosa-Guzman , b c a Eric Lefebvre , Gaston Picchio and Marie-Pierre de Be ´ thune Objective: Characterization of resistance development in virologic failure patients on the protease inhibitor darunavir administered with low-dose ritonavir (DRV/r) in the 48-week analysis of TMC114/r In Treatment-experienced pAtients Naive to lopinavir (TITAN). Design: TITAN is a randomized, controlled, open-label, phase III, noninferiority trial comparing the efficacy and safety of DRV/r with that of lopinavir/ritonavir (LPV/r) in HIV-1-infected, treatment-experienced, LPV-naive patients. The primary endpoint was the proportion of patients with HIV-1 RNA less than 400 copies/ml at week 48. Methods: Patients received DRV/r 600/100 mg twice daily (n¼ 298) or LPV/r 400/ 100 mg twice daily (n¼ 297), and an optimized background regimen. Patients who lost or never achieved HIV-1 RNA less than 400 copies/ml after week 16 were considered virologic failure patients. Genotyping and phenotyping were performed. Results: The virologic failure rate in the DRV/r arm (10%, n¼ 31) was lower than in the

Journal

AIDSWolters Kluwer Health

Published: Sep 1, 2009

There are no references for this article.